From the Genesys Regional Medical Center and Michigan State University.
Correspondence to: Kimberly R. Barber, PhD, Genesys Regional Medical Center, 1 Genesys Pkwy, Grand Blanc, MI 48439; e-mail: email@example.com.
Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).
© 2012 American College of Chest Physicians
We thank Dr Manthous for his interest in our recent article in CHEST1 and appreciate his comments. Our article concluded that the use of short-acting β-agonist albuterol and a short-acting anticholinergic ipratropium bromide in the recommended commonly used doses and frequency appear not to have a clinically significant detrimental effect on heart rate and rhythm.1
The study was a real-life bedside clinical study in the ICU. Our work was not to investigate the most effective dose or delivery method of aerosolized bronchodilator in this population. Most patients had airflow obstruction, but some had ARDS and other respiratory failures requiring mechanical ventilation. Metered-dose inhalers (MDIs) were not used in this study. All treatments were previously written by attending physicians to be given by jet nebulizers. The dose of albuterol sulfate was 2.5 mg in a total volume 3 mL (in addition to ipratropium bromide 500 μg), alternating with two different doses of levalbuterol, 0.63 mg and 1.25 mg. These treatments were delivered every 4 to 6 h. The jet nebulizer used was the Micro Mist Nebulizer (Hudson RCI). For patients receiving mechanical ventilation, the Valved Tee Adapter (Thayer Medical Corporation) was used with the Hudson nebulizer. We used the modified protocol of Hess et al as described by Dhand and Tobin2 to deliver the nebulized bronchodilator treatment.
We do not routinely measure airway resistance by the rapid airway occlusion method. We observed peek airway pressure, resistive airway pressure, and changes in auto-positive end-expiratory pressure. All patients were given the same dose and intervals. This is the most common clinically relevant method used in ICUs currently. Dhand and Tobin2 noted that both nebulizers and MDIs are effective at delivering aerosols to the lower respiratory tract of patients receiving mechanical ventilation when careful attention is given to technique. Jantz and Collop3 concluded that in patients receiving mechanical ventilation, four to 10 puffs from an MDI and 2.5 to 5.0 mg of albuterol through a small volume nebulizer every 4 h is the most recommended dose. Sims4 noted that clinical trial evidence suggests that when used with the proper technique, various devices are equally effective.
Our conclusion agrees with that of Dhand and Tobin2 that adverse cardiac effects are unlikely to occur with doses recommended in clinical practice. Much higher doses (7.5-15.0 mg albuterol delivered through a small volume nebulizer), as Dr Manthous has demonstrated, could cause sinus tachycardia and premature beats.5 However, we consider these doses to be experimental rather than clinically recommended.
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited:
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.